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The evolutionary conserved Foxo transcription
factors are important regulators of quiescence and
longevity. Although, Foxo1 is known to be important
in regulating CD8+ T cell trafficking and homeostasis,
its role in functional differentiation of antigen-stimu-
lated CD8+ T cells is unclear. Herein, we demonstrate
that inactivation of Foxo1 was essential for instruct-
ing T-bet transcription factor-mediated effector
differentiation of CD8+ T cells. The Foxo1 inactivation
was dependent on mTORC1 kinase, given that
blockade of mTORC1 abrogated mTORC2-mediated
Akt (Ser473) kinase phosphorylation, resulting in
Foxo1-dependent switch from T-bet to Eomesoder-
min transcription factor activation and increase in
memory precursors. Silencing Foxo1 ablated in-
terleukin-12- and rapamycin-enhanced CD8+ T cell
memory responses and restored T-bet-mediated
effector functions. These results demonstrate an
essential role of Foxo1 in actively repressing effector
or terminal differentiation processes to promote
memory CD8+ T cell development and identify the
functionally diverse mechanisms utilized by Foxo1
to promote quiescence and longevity.
INTRODUCTION
The availability and abundance of extracellular cues like antigen,
costimulation, and cytokines program differentiation of naive
CD8+ T cells for various effector and memory functions (Curt-
singer et al., 2003). The role of these cell-extrinsic factors in regu-
lating expression of master transcription factors that determine
choice between short-lived effector and long-lived memory
CD8+ T cells is being increasingly appreciated (Intlekofer et al.,
2005; Joshi et al., 2007). Notably, the presence of proinflamma-
tory cytokines like IL-12 enhance expression of transcription
factors like T-bet to promote differentiation of CD8+ T cells into
short-lived effectors, rather than long-lived memory cells (Joshi
et al., 2007; Takemoto et al., 2006). In contrast, the transcription
factor Eomesodermin (Eomes), which is required for important
aspects of memory CD8+ T cell generation, is dampened by374 Immunity 36, 374–387, March 23, 2012 ª2012 Elsevier Inc.IL-12 (Intlekofer et al., 2005; Rao et al., 2010). Because inflam-
matory cytokines like IL-12 exert pluripotent effects on host
immunity, rational strategies to regulate effector versus memory
CD8+ T cell differentiation will require targeting cell-intrinsic
mechanisms that regulate expression of transcriptional factors
like T-bet and Eomes.
Several studies have identified a key role for the energy sensi-
tive kinase mammalian target of rapamycin (mTOR) in regulating
effector and memory differentiation of CD8+ T cells by regulating
expression of master transcriptional factors T-bet and Eomes
(Araki et al., 2009; Pearce et al., 2009; Rao et al., 2010). The
mTOR protein is an evolutionarily conserved member of the
phosphatidylinositol-3-OH kinase (PI3K)-related kinase family,
whose ability to complex with various adaptors gives rise to
two known variants, namely mTORC1 and mTORC2 (Wulls-
chleger et al., 2006). The activation of mTORC1 can occur by
signals generated via the PI3K and Akt pathways, and its ability
to regulate activity of its downstream effectors like p70 S6 kinase
(S6K) and translation repressor protein 4EBP1 imparts mTORC1
with multiple essential functions such as protein translation, cell
cycle regulation, differentiation, and survival (Wullschleger et al.,
2006). In contrast, the upstream modulators of mTORC2 are
yet to be fully determined, although the phosphorylation of
Akt on Ser 473 (S473) has been used as a functional measure
of mTORC2 activity (Guertin et al., 2006). Although TORC1
activity is essential for type I differentiation in both CD4+ and
CD8+ T cells (Delgoffe et al., 2011; Rao et al., 2010), two indepen-
dent studies using Rictor/ CD4+ T cells have shown divergent
requirements for mTORC2 in T helper 1 (Th1) cell differentiation
(Delgoffe et al., 2011; Lee et al., 2010). Furthermore, the role of
mTORC2 in effector and memory CD8+ T cell differentiation
and the interplay between the two mTOR complexes for the
regulation of CD8+ T cell differentiation have not yet been re-
ported. In addition, the mechanisms by which mTORC1 regulate
transcriptional programs that impart terminal differentiation
versus self-renewal potential remains enigmatic.
The forkhead box (Fox) family of transcription factors,
which are mammalian orthologs of the Caenorhabditis elegans
longevity gene DAF-16, have an evolutionarily conserved func-
tion in the regulation of organismal longevity, energy metabo-
lism, and tumor suppression (Lin et al., 1997; Paik et al., 2007).
There are four members of the Foxo gene family in mammals,
Foxo1, Foxo3, Foxo4, and Foxo6, which regulate key aspects
of cell physiology, such as cell cycle progression, survival, differ-
entiation, nutrient sensing, and response to stress (Burgering,
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Foxo1 Regulates CD8+ T Cell Functional Fate2008; Salih and Brunet, 2008). Many of these processes are also
known targets of the mTOR protein complexes (Wullschleger
et al., 2006). In addition to a variety of posttranslational modifica-
tions, the activity of Foxo proteins is mainly regulated by the
PI3K-Akt mediated phosphorylation on three conserved sites,
leading to nuclear-to-cytoplasm export, degradation, and
decrease in transcriptional activity (Salih and Brunet, 2008). In
the immune system, Foxo3a-deficient T cells have been shown
to undergo spontaneous proliferation and increased differentia-
tion toward the Th1 cell phenotype (Lin et al., 2004). Recently,
two of the Foxo proteins, Foxo1 and Foxo3a, were shown to
cooperatively enhance FoxP3 expression and dictate regulatory
T (Treg) cell lineage commitment (Harada et al., 2010; Kerdiles
et al., 2010). In addition, Foxo1 deficiency leads to impaired
T cell trafficking and homeostasis partly due to its ability to regu-
late expression of the transcription factor Klf-2 and IL-7 receptor
alpha (IL-7Ra) (Gubbels Bupp et al., 2009; Kerdiles et al., 2009;
Ouyang et al., 2009), factors known to be enhanced upon rapa-
mycin-mediated mTORC1 inhibition (Araki et al., 2009; Sinclair
et al., 2008). Despite the known ability of Foxo proteins to
promote cellular and organismal longevity, its role in regulating
CD8+ T cell differentiation for effector and memory functions
has not been reported.
Herein, by employing a reductionist and in vivo approach, we
identify an essential role for Foxo1 in regulating T-bet and Eomes
expression for effector versus memory functional fate of CD8+
T cells. Our results demonstrate that instructions that program
naive CD8+ T cells for type I effector differentiation inactivate
Foxo1 via mTORC1- andmTORC2-dependent Akt phosphoryla-
tion. Foxo1 actively represses type I effector maturation by
blocking T-bet expression and promotes Eomes gene transcrip-
tion and memory precursor phenotype. Inhibition of mTORC1
enhances Foxo1 activity, which is essential for rapamycin-medi-
ated block in T-bet and increase in Eomes expression. Impor-
tantly, experiments with shRNA knockdown implicate an essen-
tial role for Foxo1 in persistence and antigen-recall responses.
These results have identified a critical role for Foxo1 in regulating
transcriptional programs to determine functional differentiation
of CD8+ T cells into effector and memory cell subsets.
RESULTS
Instructions that Program Naive CD8+ T Cells for Type I
Effector Differentiation Inactivate Transcription Factor
Foxo1
The differentiation of naive CD8+ T cells into robust effector cells
occurs at the expense of memory (Joshi et al., 2007; Williams
and Bevan, 2007). Given that Foxo1 promotes phenotype asso-
ciated with memory precursor cells (CD62L, IL-7Ra and Bcl-2)
(Kerdiles et al., 2009; Ouyang et al., 2009), we hypothesized
that extracellular instructions, such as antigen (Ag), costimula-
tion (B7.1), and proinflammatory cytokine (IL-12), that program
type I effector functions in CD8+ T cells must inhibit Foxo1
expression and/or functions. To test this notion, we first verified
the ability of IL-12 to regulate Foxo1 phosphorylation in Ag and
B7.1 (Ag+B7.1)-stimulated OT-I cells. Stimulation of naive OT-I
cells with Ag+B7.1 induced rapid (2 hr) but transient phosphory-
lation of Foxo1, given that the optimal phosphorylation observed
at 12 hr was reduced to baseline levels by 48 hr (Figure 1A).Notably, addition of IL-12 produced enhanced and persistent
phosphorylation of Foxo1, with maximum differences observed
at later time-points (Figure 1A). These results demonstrate that
instructions that program naive CD8+ T cells for type I effector
differentiation enhance and sustain the phosphorylation of tran-
scription factor Foxo1.
Because phosphorylation of Foxo1 leads to its nuclear export,
degradation, and loss of transcriptional activity, we used Image-
Stream-based flow cytometry analysis to determine whether
Ag+B7.1 and/or IL-12 stimulation promotes an increase in cyto-
plasmic amounts of Foxo1. As shown in (Figure 1B), Ag+B7.1
stimulation shifted the predominantly nuclear Foxo1 in naive
OT-I cells to the cytoplasm, which was further enhanced in the
presence of IL-12. In addition, the increased phosphorylation
and cytoplasmic retention of Foxo1 in IL-12-conditioned OT-I
cells was associated with a marked reduction in total Foxo1
protein content (Figure 1C). Notably, the reduction in Foxo1 total
protein amounts occurred only at later time points (72 hr).
Furthermore, we observed a significant decrease in Klf-2
mRNA expression (a direct gene target of Foxo1 in T cells
[Kerdiles et al., 2009]) (Figure 1D) and an increase in cell cycle
progression (Figure 1E) (Foxo transcription factors inhibit cell
cycle progression [Salih and Brunet, 2008]); thereby demon-
strating a loss of Foxo1 activity in IL-12 conditioned OT-I cells.
Collectively, these results identify Foxo1 as a target of instruc-
tions that program naive CD8+ T cells for type I effector differen-
tiation, and suggests a potential role for Foxo1 in type I effector
differentiation of CD8+ T cells.
Instructional Augmentation of mTORC1 Is Required
for Increased mTORC2 Activity
The phosphorylation of Foxo1 is controlled, in part, by phosphor-
ylation of Akt at Thr308 (T308) (downstream of PI3K) and S473
(hydrophobic motif, downstream of mTORC2). To characterize
the pathways utilized by extracellular instructions to augment
Foxo1 phosphorylation in CD8+ T cells, we evaluated the ability
of Ag+B7.1 and/or IL-12 to induce Akt phosphorylation in OT-I
cells. As shown in (Figure 2A), Ag+B7.1 stimulated OT-I cells
rapidly (2 hr) enhanced phosphorylation of Akt at T308, which
was further enhanced and sustained at late time points by
IL-12. In contrast, the induction of Akt phosphorylation at S473
was delayed and was enhanced only by 12–24 hr (Figure 2B).
However, similar to Akt T308 phosphorylation, the Ag+B7.1-
induced Akt S473 phosphorylation was transient and was main-
tained at higher levels only in the presence of IL-12 (Figure 2B). In
addition, the increase in phosphorylation of Akt at T308 and
S473 required PI3K activity (Figure S1A available online), which
is consistent with an upstream role for PI3K in regulating
PDK1-mediated Akt T308 phosphorylation andmTORC2 activity
(Wullschleger et al., 2006). Because Akt phosphorylation on
T308 preceded S473, it is reasonable to suggest that the PI3K-
mediated Akt activation precedes mTORC2 activation. Overall,
these observations identify a role for instructions to enhance
and sustain mTORC2 activity in CD8+ T cells and suggest a
potential role for mTORC2 in IL-12 mediated type I effector
differentiation.
Previously, we have reported that the presence of IL-12 during
Ag+B7.1 stimulation induces PI3K-Akt-dependent sustained
mTORC1 activity in OT-I cells (Rao et al., 2010). Although, theImmunity 36, 374–387, March 23, 2012 ª2012 Elsevier Inc. 375
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Figure 1. Instructions that Program Naive CD8+ T Cell for Type I Effector Maturation Inactivate Transcription Factor Foxo1
(A–E) Naive OT-I cells stimulated with Ag (SIINFEKL, 10nM) plus B7.1 (Ag+B7.1) (±) IL-12 (2 ng/ml) were evaluated for (A) phosphorylation of Foxo1 by intra-
cytoplasmic staining (ICS) and flow cytometry at the indicated time points and (B) subcellular localization of Foxo1 by ImageStream-based flow cytometry at
48 hr. Representative examples of bright-field (BF) and total Foxo1-FITC and DAPI and a merge image of the two stains are shown. On the far right, the top bar
graph represents the similarity coefficient between total Foxo1 and DAPI, obtained from pixel by pixel statistical analysis of each cell (n = 10000) analyzed. The
bottom bar graph represents the intensity of Foxo1 protein in the cytoplasm, *p < 0.019. Experiments shown in this figure are representative of at least three (A–C)
and two (D and E) independent experiments with similar outcomes. (Data are represented at mean ± SEM.)
(C) Total Foxo1 protein by ICS at 72 hr.
(D) mRNA for Klf-2 at 48 hr by RT-PCR; *p < 0.029.
(E) Cell cycle analysis by propidium iodide labeling at 48 hr; *p < 0.033.
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Foxo1 Regulates CD8+ T Cell Functional Fateupstreammechanisms underpinningmTORC2 activation remain
elusive, recent studies have suggested that mTORC1 and
mTORC2 may be linked via ribosomal proteins (Xie and Guan,376 Immunity 36, 374–387, March 23, 2012 ª2012 Elsevier Inc.2011). To examine a possible role for Ag+B7.1+IL-12 enhanced
mTORC1 in mTORC2 activity, we blocked mTORC1 activity by
rapamycin and evaluated for Akt S473 as a functional measure
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Figure 2. mTORC1 Activity Is Required for Enhanced mTORC2 Activity
(A and B) Naive OT-I cells stimulated with Ag+B7.1 (±) IL-12 and rapamycin (20 ng/ml) were evaluated by ICS at the indicated time points for (A) Akt phos-
phorylation at T308 and (B) Akt phosphorylation at S473. For mTOR inhibition, rapamycin was added 30 min prior to addition of Ag+B7.1+IL-12.
(C) Naive OT-I cells stimulated with Ag+B7.1 (and/or) IL-12 were transduced with control or Raptor RNAi-GFP retroviral vector (RV), cultured for 4 days,
restimulated, and evaluated for Akt T308 and S473 phosphorylation.
(D) Naive OT-I cells stimulated with Ag+B7.1 (and/or) IL-12 were transduced with control or DN-Akt GFP RV, cultured for 4 days, restimulated, and evaluated for
Foxo1 phosphorylation. Experiments shown are representative of at least three (A and B) and two (C andD) independent experiments with similar outcomes. (See
also Figure S1.)
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Foxo1 Regulates CD8+ T Cell Functional Fateof mTORC2 activity. Indeed, mTORC1 inhibition (rS6 phosphor-
ylation [S6p]; Figure S1B) blocked the ability of IL-12 to sustain
phosphorylation of Akt at S473 at late time points (24–72 hr) (Fig-
ure 2B). Notably, rapamycin treatment consistently induces an
acute increase in Akt S473 phosphorylation in OT-I cells, as re-
ported previously in other cell types (Sarbassov et al., 2006),
which may be due in part to a cell stress response. The mTOR
complex-2 is considered to be rapamycin insensitive, and the
inability of rapamycin to inhibit Akt S473 phosphorylation at early
time points confirms this notion. This is further substantiated by
the fact that short-term rapamycin treatment (4 hr) that causes
acute mTORC1 inhibition failed to inhibit mTORC2 activity at
later time points (48 hr) (Figure S1C), consistent with the require-
ment of prolonged rapamycin treatment to inhibit mTORC2
activity (Sarbassov et al., 2006). Importantly, mTORC1 inhibition
causes no measurable changes in Akt phosphorylation on T308(Figure 2A), indicating that Akt T308 is upstream of mTORC1,
whereas mTORC2 and Akt S473 are downstream of mTORC1.
These observations are further supported by the fact that inhibi-
tion of PI3K (PI3K acts upstream of mTORC1) affects phosphor-
ylation on both Akt residues (Figure S1A), whereas mTORC1
inhibition affects only mTORC2-mediated Akt S473 phosphory-
lation, but not PI3K-mediated phosphorylation on T308.
To confirm the requirement of mTORC1 in sustained mTORC2
activity observed in Ag+B7.1+IL-12-stimulated CD8+ T cells, we
specifically disruptedmTORC1 activity by using retrovirus based
RNA-interference (RNAi) to knock down the adaptor gene
Raptor. Retrovirus-infected cells marked by GFP cells were re-
stimulated and evaluated 48 hr poststimulation for Akt S473
and T308 phosphorylation in Raptor or control retrovirus-
infected cells. Identical to our observations with rapamycin treat-
ment (Figures 2A and 2B), specific knockdown of mTORC1Immunity 36, 374–387, March 23, 2012 ª2012 Elsevier Inc. 377
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Foxo1 Regulates CD8+ T Cell Functional Fate(S6p; Figure S1D) abrogated IL-12-enhanced mTORC2 activity,
with no detectable changes in Akt phosphorylation at T308 (Fig-
ure 2C). These results confirm the upstream role of mTORC1 in
sustained mTORC2-mediated S473 phosphorylation of Akt in
CD8+ T cells and uncover the existence of crosstalk between
the two TOR complexes. mTORC2 has the ability to regulate
type I effector functions in CD4+ T cells (Lee et al., 2010), and
identification of a cross-regulatory pathway between the two
TOR complexes sheds new light into their role in regulating
T cell functional differentiation.
To directly test the requirement for increased Akt activity in
IL-12 enhanced Foxo1 phosphorylation, we ectopically ex-
pressed a dominant-negative form of Akt (DN-Akt) in IL-12-
conditioned OT-I cells and evaluated for Foxo1 phosphoryla-
tion. Indeed, DN-Akt expression, which dampened Akt T308
and S473 phosphorylation (Figure S1E), abrogated IL-12
enhanced Foxo1 phosphorylation (Figure 2D), corresponding
with an increase in expression of Foxo1 target genes; indica-
tive of its transcriptional activity (Figure S1F). These results
confirm that Ag+B7.1- and IL-12-mediated Akt phosphoryla-
tion is required for enhanced Foxo1 phosphorylation in CD8+
T cells.
mTORC1 Inactivates Foxo1 via Akt-Dependent
Mechanisms
From our observations that IL-12 enhances Foxo1 phosphoryla-
tion via Akt dependent mechanisms, and that IL-12-enhanced
mTORC1 activity is required to sustain mTORC2-dependent
Akt S473 phosphorylation, we envisaged that sustained
mTORC1 activity was required for increased phosphorylation
and inactivation of Foxo1. To test this notion, we stimulated
naive OT-I cells with Ag+B7.1+IL-12 in the presence of rapamy-
cin and performed kinetic analysis of Foxo1 phosphorylation.
Similar to rapamycin-induced block in Akt S473 phosphorylation
(Figure 2B), the enhanced and sustained phosphorylation of
Foxo1 in IL-12-conditioned OT-I cells was lost upon mTORC1
inhibition (Figure 3A). The decrease in phosphorylation was
accompanied by a change in its subcellular localization, given
that mTORC1 inhibition led to a significant decrease in Foxo1
protein in the cytoplasm and a subsequent increase in its nuclear
content (Figure 3B). Furthermore, inhibition of mTORC1 resulted
in enhanced total Foxo1 protein levels (Figure 3C), along with
corresponding increases in Foxo1 target genes (Figures S2A–
S2C). These results demonstrate an essential role for mTORC1
in regulating Foxo1 activity in CD8+ T cells and implicate
Foxo1 as a potential intermediary in mTORC1 regulated CD8+
T cell differentiation.
We next evaluated whether the loss of Akt phosphorylation
upon rapamycin treatment is responsible for decrease in phos-
phorylation of Foxo1. To test this, we transduced rapamycin-
treated, IL-12-conditioned OT-I cells with myristoylated-Akt
(constitutively active form, myr-Akt) and evaluated for Foxo1
phosphorylation. Indeed, active Akt restored the loss of Foxo1
phosphorylation observed upon rapamycin treatment (Figure 3D)
and led to a decrease in Foxo1 transcriptional activity (Klf-2
mRNA expression) (Figure S2D). These results demonstrate the
ability of mTORC1 to inactivate Foxo1, via Akt dependent mech-
anisms, and indicate a potential role for Foxo1 in mTORC1-
regulated T-bet expression in CD8+ T cells.378 Immunity 36, 374–387, March 23, 2012 ª2012 Elsevier Inc.Inactivation of Foxo1 Is Required for Enhanced T-bet
Expression in CD8+ T Cells
Given thatmTORC1 inhibition increases Foxo1 activity (Figure 3),
inhibits T-bet expression, and blocks type I effector maturation
(Rao et al., 2010), we hypothesized that the ability of IL-12 to
enhance Foxo1 phosphorylation and reduce its activity is essen-
tial for enhanced and sustained T-bet expression in CD8+
T cells. To test this notion, we transduced Ag+B7.1 and/or
IL-12-conditioned OT-I cells with Foxo1-ER-Thy1.1 retroviral
vector, wherein the expression of Foxo1 is regulated by Tamox-
ifen (Tm.). Addition of Tm led to an increase in total Foxo1 protein
amounts in IL-12 conditioned-Thy1.1+ OT-I cells (Figure 4A),
along with an increase in Klf-2 gene expression (Figure S3A).
Thus, ectopic Foxo1 expression restores IL-12-mediated loss
of Foxo1 protein and its activity. The overexpression of Foxo1
inhibited IL-12-enhanced T-bet mRNA (Figure 4B) and protein
expression (Figure 4C), leading to a decrease in the expression
of CD122 (IL-15Rb), a direct gene target of T-bet in CD8+
T cells. Notably, Ag+B7.1-induced T-bet protein expression
was also abrogated upon ectopic Foxo1 expression (Fig-
ure S3B). To further implicate the role of Akt-Foxo1 in regulating
T-bet, we induced ectopic expression of DN-Akt (inhibits Foxo1
phosphorylation (Figure 2D) and increases its activity [Fig-
ure S3C]) in IL-12-conditioned OT-I cells. Indeed, DN-Akt abro-
gated the IL-12-mediated increase in T-bet expression (Fig-
ure 4D). These results demonstrate that transcription factor
Foxo1 can act to repress T-bet expression while promoting
expression of target genes like Klf-2 and CD62L.
To confirm the role of Foxo1 as a repressor of T-bet expres-
sion, we next evaluated for T-bet protein expression in CD8+
T cells derived from mice with a T cell-specific deficiency of
Foxo1 (Foxo1/). Because the T cells from Foxo1/ mice
have a defect in homeostatic maintenance (Gubbels Bupp
et al., 2009; Kerdiles et al., 2009), we purified CD8 SP mature
T cells from the thymus of Foxo1/ mice and confirmed the
loss of Foxo1 expression and its target genes (Figures S3D and
S3E). Remarkably, Foxo1/ CD8+ T cells showed increased
basal T-bet expression (data not shown), which was enhanced
by stimulation with Ag+B7.1 alone and with IL-12 (Figure 4E),
indicating that loss of Foxo1 itself is sufficient for promoting
T-bet expression in naive and antigen-stimulated CD8+ T cells.
These observations identify a role for Foxo1 in regulating T-bet
expression and demonstrate that the ability of IL-12 to inactivate
Foxo1 is essential for promoting T-bet expression inCD8+T cells.
Given that Foxo1 can act both as a transcriptional activator
and repressor (Salih and Brunet, 2008), we sought to determine
whether Foxo1 inhibits T-bet expression by direct DNA binding.
The Foxo family of transcription factors binds to a consensus
DNA sequence of (T/C/G)(T/C/G)T(G/A)TTTT(A/G/T) (Paik et al.,
2007). Detailed bioinformatics analysis identified three putative
forkhead-binding sites on the T-bet promoter region (Figure S3F).
To determine whether Foxo1 can directly bind within these sites,
we performed chromatin immunoprecipitation (ChIP) experi-
ments by using primer sets designed to amplify regions located
in each of these sites. We were unable to detect direct binding of
Foxo1 on the T-bet promoter at all three sites (Figure S3G).
However, binding of Foxo1 to the IL-7R locus from the same
ChIP lysates was observed (Figure S3G), suggesting that
Foxo1 inhibits T-bet expression via mechanisms that are
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Figure 3. mTORC1 Activity Is Required for Inactivation of Foxo1
(A and B) Naive OT-I cells stimulated with Ag+B7.1 (±) IL-12 and rapamycin were evaluated for (A) Foxo1 phosphorylation by ICS at the indicated time points (B)
subcellular localization of Foxo1 by ImageStream-based flow cytometry at 48 hr. Representative examples of bright-field (BF), total Foxo1-FITC and DAPI, and
a merge image of the two stains are shown. On the far right, the top bar graph represents the similarity coefficient between total Foxo1 and DAPI, obtained from
pixel-by-pixel statistical analysis of each cell (n = 10000) analyzed. The bottom bar graph represents the intensity of Foxo1 protein in the cytoplasm; *p < 0.011
and *p < 0.0086.
(C) Total Foxo1 protein expression by ICS at 72 hr.
(D) Naive OT-I cells stimulated with Ag+B7.1 (±) IL-12 and rapamycin were transduced with control or Myr-Akt GFP RV, cultured for 4 days, restimulated, and
evaluated for Foxo1 phosphorylation by ICS. Experiments shown are representative of at least three (A–C) and two (D) independent experiments with similar
outcomes. (See also Figure S2.) Data represented as mean ± SEM.
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Foxo1 Regulates CD8+ T Cell Functional Fateindependent of direct DNA binding, andmaymediate the repres-
sive action via indirect mechanisms.
Foxo1 Regulates Type I Effector Maturation
in T-bet-Dependent Manner
PDK1 can control TCR signal-induced IFN-g production via
Foxo-dependent mechanisms in CD8+ T cells (Macintyre et al.,2011). However, the role of Foxo1 in IL-12-enhanced and
sustained type I effector differentiation of CD8+ T cells has not
been reported. Given the importance of IL-12 in inactivating
Foxo1 to maintain sustained levels of T-bet expression, we pre-
dicted that Foxo1 regulates expression of key effector molecules
in CD8+ T cells in a T-bet-dependent manner. To test this notion,
we overexpressed Foxo1 in IL-12-conditioned OT-I cells andImmunity 36, 374–387, March 23, 2012 ª2012 Elsevier Inc. 379
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Figure 4. Foxo1 Represses T-bet Expression in CD8+ T Cells
(A) Naive OT-I cells stimulated with Ag+B7.1+IL-12 were transduced with Foxo1-ER-Thy1.1 RV, cultured for 4 days (±) Tm (10 nM), and evaluated for total Foxo1
protein expression on Thy1.1+ cells by ICS.
(B and C) Transduced OT-I cells from (A) were restimulated (±) Tm and evaluated for (B) T-bet mRNA expression by RT-PCR on sorted Thy1.1+ OT-I cells
(**p < 0.0023) and (C) T-bet protein and CD122 expression on Thy1.1+ cells.
(D) Naive OT-I cells stimulated with Ag+B7.1+IL-12 were transduced with control or DN-Akt GFP RV, cultured for 4 days, restimulated, and evaluated for Foxo1
phosphorylation.
(E) PurifiedCD8 SP thymocytes fromWT and Foxo1/mice were stimulatedwith anti-CD3 and anti-CD28 (±) IL-12 and evaluated 72 hr after stimulation for T-bet
protein expression. Experiments shown are representative of three (A–C) and two (D and E) independent experiments with similar outcomes. (Data are repre-
sented at mean ± SEM; see also Figure S3.)
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Foxo1 Regulates CD8+ T Cell Functional Fateevaluated their ability to express effector molecules such as
IFN-g and Granzyme-B. Overexpression of Foxo1 blocked
IL-12-enhanced IFN-g production and granzyme B expression
in OT-I cells (Figures 5A and 5B). In agreement, we also observed
increased IFN-g production and granzyme B expression from
Foxo1/ cells in the presence or absence of IL-12 (Figures 5C
and 5D). Because type I IFNs, like IFN-a, can also enhance
T-bet expression and IFN-g production in CD8+ T cells, we deter-
mined whether IFN-a also regulates Foxo1 to promote type I
effector differentiation in OT-I cells. As shown in Figures S4A380 Immunity 36, 374–387, March 23, 2012 ª2012 Elsevier Inc.and S4B, IFN-a enhances Foxo1 phosphorylation along with
an increase in IFN-g production in Ag+B7.1-activated CD8+
T cells. These results clearly demonstrate that inactivation of
Foxo1 is sufficient for promoting type I effector maturation in
CD8+ T cells.
The master regulator T-bet imparts type I effector fate in both
CD4+ and CD8+ T cells. To determine whether Foxo1 regulates
expression of IFN-g in a T-bet-dependent manner, we silenced
Foxo1 in Ag+B7.1-stimulated Tbx21/OT-I cells and evaluated
their ability to produce IFN-g. Decrease in total Foxo1 protein
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Figure 5. Foxo1 Inhibits Type I Effector Differentiation in a T-bet-Dependent Manner
(A and B) Naive OT-I cells stimulated with Ag+B7.1/+IL-12 were transduced with Foxo1-ER-Thy1.1 RV, cultured for 4 days (±) Tm (10 nM), re-stimulated, and
evaluated on gated Thy1.1+ cells for (A) IFN-g production and (B) Gzmb expression.
(C andD) Purified CD8SP thymocytes fromWT and Foxo1/micewere stimulatedwith anti-CD3 and anti-CD28 (±) IL-12 and evaluated 72 hr after stimulation for
(C) IFN-g production and (D) Gzmb expression.
(E) NaiveWT or Tbx21/OT-I cells stimulated with Ag+B7.1 (±) IL-12 were transduced with control or Foxo1 shRNA-hCD2 RV, cultured for 4 days, restimulated,
and evaluated for IFN-g production on gated hCD2+ cells; *p < 0.0275, **p < 0.0061, and n.s., not significant.
(F) Naive OT-I cells stimulated with Ag+B7.1/+IL-12 (±) rapamycin were transduced with T-bet-ER RV, cultured for 4 days (±) 4-HT (10 nM), restimulated, and
evaluated for IFN-g production; ***p < 0.0005 and **p < 0.0025. Experiments shown are representative of three (A, B, and F) and two (C–E) independent
experiments with similar outcomes. (Data are represented at mean ± SEM; see also Figure S4.)
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Figure 6. Rapamycin Inhibits T-bet Expression via Foxo1-Dependent Mechanisms
(A–C) Purified CD8 SP thymocytes from WT and Foxo1/mice were stimulated with anti-CD3 and anti-CD28 (±) IL-12 and rapamycin and evaluated 72 hr after
stimulation for (A) T-bet protein expression, (B) IFN-g production, and (C) CD62L protein expression.
(D) Naive OT-I cells stimulated with Ag+B7.1 (±) IL-12 and rapamycin were transduced with control or Myr-Akt GFP RV, cultured for 4 days, restimulated, and
evaluated for T-bet protein expression. Experiments shown are representative of two independent experiments with similar outcomes.
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Foxo1 Regulates CD8+ T Cell Functional Fateexpression, upon retroviral transduction with vector carrying
Foxo1 shRNA (Figure S4C), led to a significant increase in
IFN-g production from Ag+B7.1-treated WT OT-I cells (Fig-
ure 5E). Knockdown of Foxo1 in Tbx21/ OT-I cells failed to
increase IFN-g production, thereby indicating that Foxo1-medi-
ated regulation of IFN-g production in CD8+ T cells is T-bet
dependent. In addition, knockdown of Foxo1 in IL-12-condi-
tioned Tbx21/ OT-I cells led to modest but insignificant
increase in IFN-g production (data not shown). Importantly,
ectopic re-expression of T-bet in rapamycin-treated OT-I cells
restored IFN-g production (Figure 5F), although the direct gene
targets of Foxo1 like CD62L remained unchanged (data not
shown). These results identify the master transcriptional factor
T-bet as a downstream target of Foxo1 and demonstrate that
the ability of Foxo1 to dampen type I effector maturation in
CD8+ T cells is mediated via its actions on T-bet.382 Immunity 36, 374–387, March 23, 2012 ª2012 Elsevier Inc.Inhibition of mTORC1 Leads to Loss of T-bet Expression
via Foxo1-Dependent Mechanisms
Because mTORC1 inhibition and overexpression of Foxo1
inhibits T-bet expression, we sought to determine whether
increase in Foxo1 activity upon mTORC1 inhibition was respon-
sible for loss of T-bet expression and type I effector maturation in
CD8+ T cells. We stimulated WT or Foxo1/ CD8+ T cells with
Ag+B7.1+IL-12 in the presence or absence of rapamycin and
evaluated for T-bet protein expression and IFN-g production.
As shown in Figure 6A, inhibition of mTORC1 blocked IL-12
enhanced T-bet expression in WT CD8+ T cells, whereas rapa-
mycin treatment failed to block T-bet expression in Foxo1/
CD8+ T cells. Similarly, in agreement with its inability to curtail
T-bet expression, rapamycin treatment failed to inhibit IFN-g
production from Foxo1/ CD8+ T cells (Figure 6B). Because
Foxo1 enhances CD62L expression, we next evaluated whether
Immunity
Foxo1 Regulates CD8+ T Cell Functional Faterapamycin-mediated increases in CD62L expression requires
Foxo1. As shown in Figure 6C, rapamycin treatment failed to
enhance CD62L expression in IL-12-conditioned Foxo1/
CD8+ T cells. Taken together, these results identify Foxo1 as
an essential mTORC1 target that regulates expression of master
transcription factor T-bet for type I effector maturation in CD8+
T cells.
To confirm that the loss of Akt-dependent-Foxo1 phosphory-
lation due to mTORC1 inhibition is responsible for the decrease
in T-bet expression, we ectopically expressed myr-Akt in rapa-
mycin-treated, IL-12-conditioned OT-I cells and tested their
ability curtail T-bet expression. Indeed, active Akt restored the
loss of T-bet expression in rapamycin-treated IL-12-conditioned
OT-I cells (Figure 6D), as well as increased IFN-g production
(data not shown). These results indicate that mTORC1, via Akt-
dependent mechanisms, reduces Foxo1 activity and/or expres-
sion to enhance T-bet expression and type I effector maturation
in CD8+ T cells.
Foxo1 Regulates Eomes Gene Transcription and Is
Essential for CD8+ T Cell Persistence and Memory
Functions
Previously, we have shown that inhibition of mTORC1 skews
T-bet for Eomes expression and transitions type I effector cells
to memory precursor cells (CD62Lhi, Bcl-2hi, KLRG1lo) (Rao
et al., 2010). On the basis of our observations of Foxo1’s ability
to repress T-bet, we hypothesized that increase in Foxo1 activity
upon mTORC1 inhibition is responsible for an increase in Eomes
expression and the memory precursor phenotype in OT-I cells.
To test this notion, we first evaluated the ability of ectopic
Foxo1 expression to enhance Eomes expression in Ag+B7.1-
and/or IL-12 -conditioned OT-I cells. In agreement with the
inverse expression patterns for T-bet and Eomes (Takemoto
et al., 2006), addition of IL-12 decreased Eomes mRNA expres-
sion in antigen-activated OT-I cells, although we did not observe
any changes at the protein level (Figures 7A and 7B). Overex-
pression of Foxo1 led to significant increases in Eomes mRNA
and protein expression in Ag+B7.1- and/or IL-12-conditioned
OT-I cells (Figures 7A and 7B). These results demonstrate
Foxo1’s ability to regulate the relative expression of transcription
factors that promote effector (T-bet) versus memory (Eomes)
differentiation of CD8+ T cells. To confirm whether increase in
Foxo1 activity upon mTORC1 inhibition is responsible for
increased Eomes expression, we stimulated purified SP CD8+
T cells from WT or Foxo1/ mice with Ag+B7.1+IL-12 in the
presence or absence of rapamycin and evaluated for Eomes
protein expression. The expression of Eomes was lower in
IL-12-conditioned Foxo1/ cells in comparison to their WT
counterparts (Figure 7C), confirming the requirement of Foxo1
to induce Eomes expression in CD8+ T cells. Moreover, the
mTOR inhibition-induced increase in Eomes expression was
abrogated in Foxo1/ CD8+ T cells, thereby demonstrating
that the ability of rapamycin to increase Foxo1 activity is essen-
tial for enhanced Eomes expression in CD8+ T cells. Collectively,
these results suggest the possibility that Foxo1 might directly
regulate Eomes transcription, and as such, we inspected Eomes
promoter for putative Foxo1-binding sites and identified one
proximal (158 bp upstream of transcription start site) and two
distal Foxo1-binding sites. As shown in Figure 7D, anti-Foxo1immunoprecipitated the DNA fragments corresponding to the
proximal, but not the distal, region of Eomes promoter. These
results demonstrate that Foxo1 induces Eomes gene expression
by directly binding to Eomes promoter.
Given the ability of Foxo1 to regulate expression of memory-
associated transcription factor Eomes, we envisaged a possible
role for Foxo1 in memory CD8+ T cell differentiation. To test this
notion, we first evaluated the role of Foxo1 in regulating CD8+
T cell memory precursor phenotype. shRNA-mediated knock-
down of Foxo1 (Figure S5A) led to considerable decrease in
CD62L and CD127, and increase in KLRG1 expression (Fig-
ure S5B), indicating the requirement of Foxo1 to promote pheno-
type associated with enhanced homing to secondary lymphoid
compartments, homeostatic renewal, and long-term survival.
To directly test the role of Foxo1 in CD8+ T cell memory, we eval-
uated the persistence (day 40) and antigen recall response (day
43) of adoptively transferred Ag+B7.1- and/or IL-12- and rapa-
mycin-treated OT-I/Thy1.1+ cells, that were knocked down for
Foxo1. As previously reported, the OT-I cells treated with
rapamycin demonstrate remarkably greater persistence than
IL-12-conditioned OT-I cells (Figure 7E). Knockdown of Foxo1
significantly reduced the ability of Ag+B7.1-conditioned, IL-12-
conditioned, and/or rapamycin-treated cells to persist, as
demonstrated by the decreased frequency OT-I+Thy1.1+ cells
detected on day 40 (Figures 7E and S5C). Moreover, the ability
of OT-I cells to undergo vigorous antigen-recall clonal expansion
(Figure 7F) and effector function (IFN-g) (Figure S5D) was signif-
icantly impaired in Foxo1 shRNA-transduced cells (day 43).
These results demonstrate an essential role for transcription
factor Foxo1 in programming antigen-, IL-12-, and rapamycin-
induced CD8+ T cell persistence and functional memory
responses.
DISCUSSION
Extracellular instructions direct differentiation of naive CD8+
T cells into effector and memory cell subsets, but these subsets
occur at variance to each other because the factors that promote
terminal differentiation into short-lived effector cells will curtail
differentiation into long-lived memory cells, and vice versa. We
and others have shown a central role for energy sensitive kinase
mTOR in effector and memory differentiation process, given that
this kinase has the unique ability to integrate extracellular
instructions and regulate gene programs associated with
effector and memory functions (Araki et al., 2009; Li et al.,
2011; Pearce et al., 2009; Rao et al., 2010). However, the precise
downstream mechanisms by which mTORC1 regulate expres-
sion of these master transcriptional factor genes are not well
understood. In this study, weprovide direct evidence for a unique
role of Foxo1, downstream of mTORC1, in regulating gene pro-
grams to actively suppress effector maturation and/or terminal
differentiation and promote longevity and functional memory
responses in CD8+ T cells.
To date studies havedemonstrated the ability of Foxo1 to regu-
late properties like quiescence, homing, and survival of naive
CD8+ T cells that are required for memory responses, but its
ability to regulate transcriptional programs that determine
effector and memory functions of CD8+ T cells has not been re-
ported. Resting T cells express Foxo1, which is inactivatedImmunity 36, 374–387, March 23, 2012 ª2012 Elsevier Inc. 383
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Figure 7. Foxo1 Regulates Eomes Gene Transcription and Is Essential for Memory CD8+ T Cell Functions
(A–E) Naive OT-I cells stimulated with Ag+B7.1 (±) IL-12 were transduced with Foxo1-ER-Thy1.1 RV, cultured for 4 days (±) Tm (10nM), and evaluated on Thy1.1+
cells for (A) Eomes mRNA expression by RT-PCR (*p < 0.021,**p < 0.0091) and (B) Eomes protein expression.
(C) Purified CD8+ T cells fromWT and Foxo1/mice were stimulated with anti-CD3 and anti-CD28 (±) IL-12 and rapamycin, and evaluated 72 hr after stimulation
for Eomes protein expression.
(D) Schematic structure of the Eomes promoter with putative Forkhead-binding sites, and ChIP analysis of Foxo1 binding to the Eomes promoter in OT-I cells.
Results analyzed by RT-PCR are presented as fold of template enrichment in immunoprecipitates of Foxo1 antibody relative to control immunoprecipitation (Ig).
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Immunity
Foxo1 Regulates CD8+ T Cell Functional Fateuponantigen stimulation to enableproliferation andclonal expan-
sion.However, the regulation of Foxo1 by cytokines that program
functional differentiation of CD8+ T cells has not been character-
ized. Our results show that proinflammatory cytokine IL-12
augments the phosphorylation and inactivation of Foxo1 in
antigen-activated cells, which is essential for T-bet-mediated
type I effector functions. In addition to increasedphosphorylation,
IL-12 causes a loss in total Foxo1 protein levels, which may be
essential in their ability to impart T-bet-dependent ‘‘heritable’’
type I effector differentiation of CD8+ T cells. At this juncture, it
is not fully clear as to how IL-12 causes a loss in Foxo1 protein
levels. On the basis of our results and a recent report (Stittrich
et al., 2010), it is reasonable to suggest that IL-12 inhibits Foxo1
at the posttranscriptional level, given the fact that we observe
lossof Foxo1proteinonlyat late timepoints.Because inactivation
of Foxo1 by IL-12 leads to a loss of Klf-2 and CD62L expression,
the observations provide a mechanism for the exclusion of
effector CD8+ T cells from the secondary lymphoid organs. The
dual role for Foxo1 in augmenting Eomes, Klf-2, CD62L, IL-7Ra,
and Bcl-2 expression and dampening T-bet-mediated type I
effector differentiation affords new opportunities to regulate
CD8+ T cell differentiation for desirable health benefits.
The mTOR complexes (mTORC1 and mTORC2) have been
shown to regulate differentiation in a variety of tissues. In CD8+
T cells, signals emanating from the TCR, CD28 coreceptor,
and cytokines (IL-12, IL-7, and IL-2) have been shown to modu-
late mTORC1 activity (Li et al., 2011; Rao et al., 2010; Sinclair
et al., 2008); however, relatively little is known about the factors
that modulate mTORC2 activity in T cells. Our results have
identified PI3K-induced mTORC1 as an upstream regulator of
mTORC2 activity, such that increased mTORC1 activity pro-
moted by IL-12 is required to sustain mTORC2 activity in CD8+
T cells. A recent study demonstrated that mTORC2 can be acti-
vated by direct association with the ribosomes in yeast and
mammalian cells (Zinzalla et al., 2011). Because mTORC1 is a
direct regulator of S6 and ribosome biogenesis, it can be sug-
gested that Ag+B7.1- and/or IL-12-induced mTORC1 increases
mTORC2 activity by increasing ribosomal levels within CD8+
T cells. Although compelling, these concepts need further ex-
perimentation. Nevertheless, identifying a causal link between
mTORC1 and mTORC2 in regulating T cell differentiation is
significant, given that thesemTOR protein complexes are known
to exert distinct functions in other cell types, and by delineating
their interplay wemay be able to achieve finer regulation of CD8+
T cell functional outcomes for immunity.
The ability of mTORC1 to inhibit Foxo1 transcriptional activity
is consistent with an inverse corelation of activity between
mTORC1 and Foxo1 (Chen et al., 2010). Collectively, our obser-
vations have unraveled pathways bywhichmTORC1, depending
upon physiological state of a CD8+ T cell, may modulate Foxo1
to regulate proliferation, survival, migration, and functional differ-(E and F) Naive OT-I cells (Thy1.1+) stimulated with Ag+B7.1 (±) IL-12 and rapamy
Thy1.1+ cells, adoptively transferred (23 106 cells) into BL/6 recipients and (E) ev
after adoptive transfer. The circles indicate OT-I/Thy1.1 population and the num
(F) The recipient mice were immunized with IFA-OVA on day 40 after transfer and
numbers of adoptively transferred cells before (pre-rechallenge) and after (post-re
indicate fold expansion of CD8a+Thy1.1+ from day 40 to day 43; *p < 0.0125 and
(C–F) independent experiments with similar outcomes. (See also Figure S5.)entiation. Because Foxo1 is a direct transcriptional activator of
Klf-2 and IL-7Ra, our results have identified mechanisms by
which inhibition of mTORC1 by rapamycin leads to an increase
in trafficking of CD8+ T cells into secondary lymphoid compart-
ments and promote their survival and memory differentiation.
Importantly, the ability of Foxo1 to regulate master transcription
factor T-bet unravels a unique function for Foxo1 in CD8+ T cell
differentiation and further defines the mechanisms by which
mTORC1 controls functional differentiation of CD8+ T cells.
Although we demonstrate the ability of Foxo1 to inhibit T-bet
mRNA expression in CD8+ T cells, we did not detect direct
binding of Foxo1 on T-bet promoter. Given the inverse corelation
of expression between T-bet and Eomes, and the identification
of Eomes being a direct gene target of Foxo1, it can be envis-
aged that Foxo1 may indirectly regulate T-bet expression by
controlling expression of Eomes. In any case, further studies
are clearly warranted because better understanding of mecha-
nisms underpinning Foxo1-mediated T-bet expression in CD8+
T cells could shed light on the potential role for Foxo proteins
in immunity and/or lifespan extension.
The Foxo transcription factors play a crucial role in promoting
organismal longevity and also impart quiescence and survival to
T cells. The results obtained with knockdown of Foxo1 leading to
a loss of survival and memory functions in CD8+ T cells provide
further support for the role of Foxo1 as a longevity factor in CD8+
T cells. In addition, the inability of rapamycin to enhance Eomes
expression and memory precursor phenotype in Foxo1/ cells
provide a mechanistic basis on how inhibition of mTORC1
promotes memory CD8+ T cell differentiation. Given the role of
rapamycin and Foxo1 in lifespan extension, identification
of Foxo1’s role in repressing terminal effector differentiation of
CD8+ T cells may be harbinger of its additional role in other
tissues and its potential contribution to longevity.
In summary, we have identified Foxo1 as an important down-
stream mediator of mTORC1 that regulates key transcriptional
programs to determine effector versus memory differentiation
of CD8+ T cells. Moreover, it indicates an as-yet-unappreciated
role for Foxo1 in blocking T-bet-mediated type I effector differen-
tiation of CD8+ T cells and demonstrates its importance in
memory generation. Furthermore, these studies unravel key
molecular mechanisms by which mTORC1 matches physiologic
and metabolic state of CD8+ T cell to control growth, prolifera-
tion, and differentiation. The information offers new opportunities
to target CD8+ T cell differentiation for immunity against infec-
tious diseases and cancers.EXPERIMENTAL PROCEDURES
Mice and Reagents
The C57BL/6, CD8+ TCR transgenic Rag2/ (OT-I, WT), (OT-I Thy1.1+), and
Tbx21/ OT-I mice were bred, housed, and used in accordance with IACUCcin were transduced with control or Foxo1 shRNA-hCD2 RV, sorted for hCD2-
aluated for the frequency of adoptively transferred cells in the spleen at day 40
bers indicate percent frequency.
secondary CD8+ T cell responses were measured 3 days later. The absolute
challenge) immunization in the spleen are shown. The numbers in parenthesis
**p < 0.0087. Experiments shown are representative of three (A and B) and two
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Foxo1 Regulates CD8+ T Cell Functional Fateguidelines at RPCI. Conditional deletion of Foxo1 in T cells was achieved in
Foxo1fl/fl-Lck-Cre+/ mice by breeding Foxo1fl/fl mice as described (Gubbels
Bupp et al., 2009) with Lck.cre transgenic mice (C57BL/6NTac-TgN(Lck-
Cre); Taconic Farms). The Foxo1fl/fl WT and Foxo1fl/fl-Lck-Cre mice used in
experiments were 3-month-old sex-matched littermates and were bred,
housed, and used in accordance with IACUC guidelines at Randolph-Macon
College. The rmIL-12 was a gift from Wyeth, Inc. IFN-a was a gift from
T. Tomasi (RPCI) rmIL-7 was purchased from Peprotech. 4-HT and rapamycin
were purchased from Sigma Aldrich. LY290042 was purchased from
Calbiochem.
Antibodies and Flow Cytometry
The antibodies for flow cytometric analysis, anti-CD62L (MEL14), anti-Thy1.1
(OX-7), and isotype-matched controls were purchased from BD PharMingen.
Anti-TCR Va2 (B20.1) was purchased from Biolegend. Anti-CD8 (53-6.7), anti-
CD122 (5H.4), anti-IFN-g (XGM1.2), anti-T-bet (eBio4B10), anti-Eomesoder-
min (21Mags8), anti-KLRG1 (2F1), anti granzyme-B (16G6), anti-hCD2 (RPA-
2.10), goat anti-rabbit IgG, and anti-IL-7Ra (AR734) were purchased from
eBioscience. The following antibodies were from Cell Signaling: antibody to
S6 ribosomal protein phosphorylated at Ser 235/236 (D57.2.2E), antibody to
Akt phosphorylated at Thr 308 (C31E5E), antibody to Akt phosphorylated at
Ser473 (D9E), isotype matched control antibody (D1AE), antibody to FoxO1
phosphorylated at Ser256, and total FoxO1 antibody (L27). Immuno-stained
samples were run on BD FACS Calibur and analyzed with FCS Express
(Version 3).
Stimulation of OT-I Cells
Unless otherwise stated, naive OT-I cells were stimulated with latex micro-
spheres expressing H-2Kb-SIINFEKL and B7.1. In some experiments, the
cell line derived from embryonic fibroblasts namely, BOK (MEC.B7.SigOVA:
expressing H-2Kb, OVAp [SIINFEKL] and B7.1), was used as antigen-present-
ing cells to stimulate naive OT-I cells. The cells obtained from the thymus of
Foxo1-WT and Foxo1/ cells, were purified by negative selection (Cedarlane
Labs) and were stimulated with anti-CD3 and anti-CD28-coated latex
microspheres.
Adoptive Transfer and Evaluation of Ag-Specific CD8+ T Cells In Vivo
OT-I T cells (CD8a+/Thy1.1+) transduced with control or FoxO1 shRNA were
harvested 4 days posttransduction and adoptively transferred (2 3 106) intra-
venously into intact Thy1.2+ congenic BL/6 recipients. Recipients were rechal-
lengedwith 5 mg of chickenOVA protein andmixedwith an equal volume of IFA
(Sigma-Aldrich) via subcutaneous injection on day 40 after transfer. The
numbers of OT-I/Thy1.1+ cells were determined after staining and flow cytom-
etry evaluation. The total number of adoptively transferred cells was calculated
by multiplying the total lymphocyte count by the ratio of CD8a+/Thy1.1+ T cells
gate. For ex vivo IFN-g expression analysis, spleen cells were restimulated
in vitro with 0.2 mM SIINFEKL peptide. After 1 hr of incubation at 37C,
Brefeldin A (10 mg/ml) was added to block protein transport. After 5 hr at
37C, the cells were surface stained with antibody to CD8a and Thy1.1, fixed,
permeabilized, and intracellularly stained with antibody to IFN-g and fixed
again.
Statistical Analysis
For statistical analysis, the unpaired Student’s t test was applied. Significance
was set at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.immuni.2012.01.015.
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